Fecal microbiota transplant (FMT), or the transfer of stool from a healthy donor to a patient, has been found highly effective in reversing severe Clostridiodes difficile diarrheal infections in adults. C.
Fecal Microbiota Transplant
Transplanting human donor fecal microbiota into the colon of a patient infected with Clostridiodes difficile (C. diff) may be the best treatment for those not helped by C. diff targeted antibiotics, according to an article in the Journal of the American Osteopathic Association.
Healthy donor feces is a life-saving therapy, and the treatment provides huge cost savings -- fecal microbiota transplantation (FMT) saves at least $1.2 million each time 50 patients are treated for Clostridium difficile at a public hospital.
Nine out of 10 patients are cured by a fecal transplantation, in which feces from a donor is inserted into the patient's intestines via an endoscope or probe. For this reason the transplantation should in future be the first treatment chosen in Denmark's hospitals.
Fecal transplants have become routine treatment for nasty recurrent diarrheal infections, but trials for other conditions have hit a bum note. Now, the fecal faithful have re-examined the evidence.
A research consortium recently began enrolling patients in a clinical trial examining whether fecal microbiota transplantation (FMT) by enema—putting stool from a healthy donor in the colon of a recipient—is safe and can prevent recurrent Clostridium difficile-associated disease (CDAD), a potenti
A randomized clinical trial at Memorial Sloan Kettering Cancer Center (MSK) has shown that fecal microbiota transplants (FMTs) can reestablish the health-promoting bacteria that are often damaged by intense antibiotic treatment in people who have stem cell or bone marrow transplants for blood can
Researchers at Memorial Sloan Kettering Cancer Center have shown that autologous fecal microbiota transplantation (auto-FMT) is a safe and effective way to help replenish beneficial gut bacteria in cancer patients who require intense anti
In a paper published February 14 in Cell Host & Microbe, scientists provide a statistical model predicting which bacterial strains will engraft after FMT.